Information on drooling
Information on drooling in children with neurodisabilities for patients and parents/carers – developed in collaboration with the Bobath Centre.
Information on drooling in children with neurodisabilities for patients and parents/carers – developed in collaboration with the Bobath Centre.
Guidance for patients and parents/carers on how to administer Sialanar® orally
Guidance for patients and parents/carers on how to administer Sialanar® via feeding tubes
Guidance for patients and parents/carers on how to administer Sialanar® orally
Guidance for patients and parents/carers on how to administer Sialanar® via feeding tubes
The mTDS can be shared with parents/carers to complete to assess drooling and inform consultations.
The DIS can be shared with parents/carers to complete in order to assess drooling over a period of time, this may be a useful tool to evaluate an intervention or medication.
Case study summary of a patient ‘Tim’ who was prescribed Sialanar®
Guidance on dose conversion providing equivalent doses of Sialanar® and 1mg/5ml glycopyrronium bromide oral solutions (intended for UK HCPs only)
Proveca run educational sessions on a regular basis covering a variety of topics, register here to be the first to know what’s coming up or head to our resources section to catch up on previous sessions.
UK-SIA-24-0038 | June 2024
Reporting of side effects
UK
If you/your child experience(s) any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
Republic of Ireland
If you/your child experience(s) any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. Adverse event should be reported, reporting forms and information can be found at: www.hpra.ie.
By reporting side effects, you can help provide more information on the safety of this medicine.
Side effects should also be reported to Proveca Limited. Phone: +44 333 200 1866 E-Mail: medinfo@proveca.com